Harmony Investments vs Investments Non Current Analysis
HRMY Stock | USD 29.23 0.38 1.32% |
Trend analysis of Harmony Biosciences Holdings balance sheet accounts such as Total Current Liabilities of 84 M or Total Stockholder Equity of 490.3 M provides information on Harmony Biosciences' total assets, liabilities, and equity, which is the actual value of Harmony Biosciences to its prevalent stockholders. By breaking down trends over time using Harmony Biosciences balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Harmony |
About Harmony Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Harmony Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Harmony Biosciences Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Harmony Biosciences and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Harmony currently owns. An asset can also be divided into two categories, current and non-current.
Harmony Biosciences Balance Sheet Chart
Harmony Biosciences Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Harmony Biosciences uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Harmony Biosciences' Accumulated Other Comprehensive Income is fairly stable compared to the past year. Intangible Assets is likely to rise to about 148.8 M in 2024, whereas Total Assets are likely to drop slightly above 466 M in 2024. Add Fundamental
Total Assets
Total assets refers to the total amount of Harmony Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Harmony Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Harmony Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Harmony Biosciences Holdings are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Harmony Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Harmony Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harmony Biosciences Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At this time, Harmony Biosciences' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.8 B in 2024, whereas Selling General Administrative is likely to drop slightly above 60.8 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 18.8M | 23.4M | 24.3M | 14.7M | Total Operating Expenses | 162.4M | 234.2M | 268.8M | 178.2M |
Harmony Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Harmony Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Harmony Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 106.7M | 427.1M | 433.4M | 673.9M | 811.4M | 466.0M | |
Other Current Liab | 13.5M | 132.0M | 1.4M | 73.1M | 7.8M | 7.4M | |
Total Current Liabilities | 19.9M | 134.5M | 53.8M | 78.9M | 163.8M | 84.0M | |
Total Stockholder Equity | (11.6M) | 97.2M | 186.5M | 402.8M | 467.0M | 490.3M | |
Other Liab | 450K | 1.1M | 3.2M | 1.5M | 1.8M | 1.5M | |
Net Tangible Assets | (495.0M) | (65.2M) | 42.6M | 241.9M | 278.2M | 292.1M | |
Property Plant And Equipment Net | 1.3M | 938K | 820K | 573K | 371K | 352.5K | |
Net Debt | 73.5M | (34.4M) | (42.3M) | (52.1M) | (118.1M) | (112.2M) | |
Retained Earnings | (422.9M) | (488.2M) | (453.6M) | (272.1M) | (143.3M) | (150.4M) | |
Accounts Payable | 6.4M | 2.6M | 1.0M | 3.8M | 17.7M | 18.6M | |
Cash | 24.5M | 228.6M | 234.3M | 243.8M | 311.7M | 206.5M | |
Non Current Assets Total | 75.2M | 164.2M | 149.0M | 273.6M | 360.4M | 187.9M | |
Non Currrent Assets Other | 1.7M | 902K | 4.3M | 3.5M | 6.6M | 3.3M | |
Other Assets | 1.7M | 902K | 4.3M | 87.2M | 100.3M | 105.3M | |
Cash And Short Term Investments | 24.5M | 228.6M | 234.3M | 323.1M | 353.5M | 228.7M | |
Net Receivables | 4.3M | 22.2M | 34.8M | 54.7M | 74.1M | 77.8M | |
Common Stock Shares Outstanding | 63.7M | 56.9M | 59.2M | 61.1M | 60.4M | 64.3M | |
Liabilities And Stockholders Equity | 106.7M | 427.1M | 433.4M | 673.9M | 811.4M | 466.0M | |
Non Current Liabilities Total | 98.4M | 195.4M | 193.2M | 192.1M | 180.7M | 157.7M | |
Inventory | 1.1M | 3.8M | 4.4M | 4.3M | 5.4M | 3.5M | |
Other Current Assets | 261K | 1.3M | 3.2M | 8.8M | 5.5M | 4.0M | |
Other Stockholder Equity | 1K | 585.4M | 640.1M | 675.1M | 610.3M | 519.8M | |
Total Liab | 118.3M | 329.9M | 246.9M | 271.0M | 344.5M | 241.7M | |
Net Invested Capital | (324.9M) | 291.4M | 378.5M | 594.5M | 660.6M | 693.6M | |
Total Current Assets | 31.5M | 262.9M | 284.4M | 400.3M | 451.1M | 278.1M | |
Non Current Liabilities Other | 163K | 893K | 3.2M | 2.5M | 2.1M | 1.7M | |
Net Working Capital | 11.6M | 128.4M | 230.7M | 321.4M | 287.3M | 194.1M | |
Property Plant Equipment | 1.3M | 938K | 820K | 573K | 515.7K | 837.9K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harmony Biosciences Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Harmony Stock analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Harmony Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harmony Biosciences. If investors know Harmony will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harmony Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.43) | Earnings Share 2.13 | Revenue Per Share 9.787 | Quarterly Revenue Growth 0.313 | Return On Assets 0.1616 |
The market value of Harmony Biosciences is measured differently than its book value, which is the value of Harmony that is recorded on the company's balance sheet. Investors also form their own opinion of Harmony Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Harmony Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harmony Biosciences' market value can be influenced by many factors that don't directly affect Harmony Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harmony Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Harmony Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harmony Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.